臨床婦人科産科77巻9号

2023年09月発行

今月の臨床 専攻医必携！　免疫チェックポイント阻害薬が変える子宮がん診療

子宮体がん編

腫瘍遺伝子変異量高スコアによるペムブロリズマブ単剤のコンパニオン診断とその適応

著者： 清水裕介¹ 梶山広明¹

所属機関： ¹名古屋大学医学部産婦人科

ページ範囲：P.904 - P.911

文献概要

●FoundationOne^® CDxがんゲノムプロファイリングがペムブロリズマブのコンパニオン診断薬として承認された．

●化学療法後に増悪したTMB-Highを有する進行・再発の固形がん（標準的な治療が困難な場合に限る）に対して，ペムブロリズマブが適応承認された．

●ペムブロリズマブをはじめ，子宮体がんの診療が大きく変わりつづけるなか，常に情報を更新し最良の治療方針を検討しつづけることが重要である．

参考文献

1）Sung H, et al : Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71 : 209-249, 2021

2）Brooks RA, et al : Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 69 : 258-279, 2019

3）Okazaki T, et al : A rheostat for immune responses : the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14 : 1212-1218, 2013

4）Marabelle A, et al : Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study. J Clin Oncol 38 : 1-10, 2020

5）Marabelle A, et al : Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21 : 1353-1365, 2020

6）Stenzinger A, et al :Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer 58 : 578-588, 2019

7）Fancello L, et al : Tumor mutational burden quantification from targeted gene panels : major advancements and challenges. J Immunother Cancer 7 : 183, 2019

8）Chan TA, et al : Development of tumor mutation burden as an immunotherapy biomarker : utility for the oncology clinic. Ann Oncol 30 : 44-56, 2019

9）Chalmers ZR, et al : Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9 : 34, 2017

10）Hendriks L, et al : New windows open for immunotherapy in lung cancer. Nature 558 : 376-377, 2018

11）Pardoll DM : The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 : 252-264, 2012

12）Michot JM, et al : Immune-related adverse events with immune checkpoint blockade : a comprehensive review. Eur J Cancer 54 : 139-148, 2016

13）Brahmer JR, et al : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36 : 1714-1768, 2018

14）キイトルーダ適正使用ガイド．p.6，MSD，2022年10月

15）Maher VE, et al : Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol 37 : 2730-2737, 2019

16）Hammond ME, et al : American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28 : 2784-2795, 2010

17）Khoury T, et al : Delay to formalin fixation effect on breast biomarkers.Mod Pathol 22 : 1457-1467, 2009

18）Makker V, et al : Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386 : 437-448, 2022

19）Eskander R, et al : Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med, 2023（in press）